The REMAR (Rhein-Main-Registry)-Study: Prospective evaluation of oncotype DX® Assay in Addition to Ki-67 for adjuvant treatment decisions in early breast cancer. (October 2020) - Thill, M.; Anastasiadou, L.; Solbach, C.; Möbus, V.; Baier, P.; Ackermann, S.; Giesecke, D.; Schulmeyer, E.; Gabriel, B.; Mosch, D.; Buchen, S.; Krapfl, E.; et al.